News & Views
Licencing Agreement to Further Preclinical Disease Modelling
Jun 16 2019
Danish life sciences business Bioneer A/S, has been granted access to ERS Genomics’ CRISPR/Cas9 genome editing technology intellectual property, to generate a range of human cell based disease models.
The licensing agreement, will enable Hørsholm-based Bioneer to generate and commercialise CRISPR-edited cell based models, broadening its core capabilities and expanding on Bioneer's expertise in biomedical research support.
Eric Rhodes, CEO of ERS Genomics, said: “Bioneer has proven expertise in a broad array of biomedical fields. Adding CRISPR/Cas9 to their toolbox ensures they remain on the leading edge of technology. We are very pleased that Bioneer chose to expand on its service offering by licensing CRISPR/Cas9 technology through ERS Genomics."
“This cutting-edge technology will complement Bioneer’s competences in advanced preclinical disease modelling.” stated Lars H. Pedersen, CEO of Bioneer. Company CSO Christian Clausen added “Bioneer is working with both industry and academia to solve complex disease relevant questions by using advanced disease modelling. The CRISPR/Cas9 tools will enable clients and collaborators to precisely tailor their preclinical modelling strategies to their specific needs for predictive in vitro models.”
Financial details of the agreement were not disclosed.
Digital Edition
International Labmate Buyers' Guide 2024/25
June 2024
Buyers' Guide featuring: Product Listings & Manufacturers Directory Chromatography Articles - Enhancing HPLC Field Service with fast-response, non-invasive flowmeters - Digital transformatio...
View all digital editions
Events
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia
Jul 31 2024 Chengdu, China